Tg Therapeutics (TGTX) Common Equity (2011 - 2026)
Tg Therapeutics (TGTX) posted quarterly Common Equity of $583.1 million for Q1 2026, up 145.75% year-over-year from $237.3 million in Q1 2025, and down 10.01% quarter-over-quarter from $648.0 million in Q4 2025.
Tg Therapeutics (TGTX) Common Equity (2011 - 2026) Analysis & Trends
Tg Therapeutics' Common Equity history runs 16 years deep, the most recent figure standing at $583.1 million for Q1 2026.
- In Q1 2026, Common Equity rose 145.75% year-over-year to $583.1 million; the TTM figure through Mar 2026 stood at $583.1 million (up 145.75% YoY), while the FY2025 annual figure was $648.0 million, up 191.42% from the prior year.
- Common Equity for Q1 2026 stood at $583.1 million, down from $648.0 million in the prior quarter.
- The five-year high for Common Equity was $648.0 million in Q4 2025, with the low at $27.4 million in Q1 2023.
- The 5-year median for Common Equity is $170.4 million (2022), against an average of $232.7 million.
- The sharpest annual moves came in 2023 and 2024: Common Equity tumbled 83.9% in 2023, then soared 483.64% in 2024.
- Tg Therapeutics' Common Equity stood at $58.6 million in 2022, then jumped by 173.95% to $160.5 million in 2023, then jumped by 38.54% to $222.4 million in 2024, then surged by 191.42% to $648.0 million in 2025, then decreased by 10.01% to $583.1 million in 2026.
- Business Quant data shows TGTX's Common Equity at $583.1 million in Q1 2026, $648.0 million in Q4 2025, and $607.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Tg Therapeutics | 7.46 Bn | 6.78 Bn | 199.14 Mn | 604.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 604.08 Mn |
| Mar 31, 2026 | 583.13 Mn |
| Dec 31, 2025 | 648.02 Mn |
| Sep 30, 2025 | 607.22 Mn |
| Jun 30, 2025 | 276.43 Mn |
| Mar 31, 2025 | 237.29 Mn |
| Dec 31, 2024 | 222.36 Mn |
| Sep 30, 2024 | 192.16 Mn |
| Jun 30, 2024 | 177.57 Mn |
| Mar 31, 2024 | 160.11 Mn |
| Dec 31, 2023 | 160.50 Mn |
| Sep 30, 2023 | 164.77 Mn |
| Jun 30, 2023 | 40.45 Mn |
| Mar 31, 2023 | 27.43 Mn |
| Dec 31, 2022 | 58.59 Mn |
| Sep 30, 2022 | 100.48 Mn |
| Jun 30, 2022 | 129.04 Mn |
| Mar 31, 2022 | 170.39 Mn |
| Dec 31, 2021 | 237.15 Mn |
| Sep 30, 2021 | 311.52 Mn |